AKT1E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363.

Peter JohnNatalie WaldtJosephine LiebichChristoph KesselerStefan SchnabelFrank AngensteinI Erol SandalciogluCordula ScherlachFelix SahmElmar KirchesChristian Mawrin

Published in: Neuropathology and applied neurobiology (2021)

Our data suggest that AKT1E17K mutated meningiomas are a promising selective target for AZD5363.

Keyphrases

signaling pathway
cell proliferation
big data
replacement therapy
deep learning
optical coherence tomography